Allergic Rhinitis (ICD-10: J30.4)
Conditions
Interventions
Control group:Conventional medication + sham acupoint injection (saline) + sham taVNS stimulation
Drug + acupoint injection + sham taVNS group:Conventional medication + triamcinolone acupoint injection at ST36 + sham taVNS stimulation
Drug + sham acupoint + real taVNS group:Conventional medication + sham acupoint injection (saline) + real taVNS stimulation
Drug + acupoint injection + real taVNS group:Conventional medication + triamcinolone acupoint injection at ST36 + real taVNS stimulation
Sponsors
The First Affiliated Hospital of Anhui Medical University
Eligibility
Sex/Gender
All
Age
18 Years to 65 Years
Inclusion criteria
Inclusion criteria: 1)Meet the diagnostic criteria for moderate-to-severe allergic rhinitis as defined in the "Chinese Guidelines for Diagnosis and Treatment of Allergic Rhinitis (2022, Revised Edition)", with a baseline TNSS = 6 during the screening period; 2)Aged between 18 and 65 years, male or female; 3)Conscious, cooperative, with good compliance, and without severe chronic or psychiatric diseases; 4)Considered suitable for the study by the principal investigator; 5)Voluntarily sign the informed consent form and agree to complete the entire follow-up process.
Exclusion criteria
Exclusion criteria: 1)Presence of acute or chronic sinusitis, otitis media, or other ENT infectious diseases; 2)History of sinus or nasal surgery within the past 6 months; 3)Drug-induced rhinitis or chronic epistaxis; 4)Severe nasal septal deviation or other significant anatomical abnormalities affecting respiration; 5)Severe respiratory, hematologic, cardiovascular, or psychiatric diseases; 6)Pregnant or lactating women, or those with skin ulcers, contact dermatitis, or other skin disorders; 7)Glucocorticoid-dependent patients, those who have received systemic corticosteroids within the past 4 weeks, or specific allergen immunotherapy within the past 6 months; 8)Currently receiving or previously received allergen immunotherapy; 9)Presence of implants such as cochlear implants, vagus nerve stimulators, or cardiac pacemakers; 10)Any other conditions deemed by the investigator to potentially affect participation or data interpretation.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Total Nasal Symptom Score (TNSS);Rhinoconjunctivitis Quality of Life Questionnaire (RQLQ); | — |
Secondary
| Measure | Time frame |
|---|---|
| Total Ocular Symptom Score (TOSS);Serum Th1/Th2 cytokine levels;Total serum IgE and specific IgE;Peripheral blood eosinophil count; | — |
Countries
China
Contacts
Public ContactYehai Liu
The First Affiliated Hospital of Anhui Medical University
Outcome results
None listed